Rapamycin attenuated podocyte apoptosis via upregulation of nestin in Ang II-induced podocyte injury

Mol Biol Rep. 2022 Mar;49(3):2119-2128. doi: 10.1007/s11033-021-07029-x. Epub 2022 Feb 11.

Abstract

Background: Angiotensin II (Ang II) contributes to the progression of glomerulosclerosis, mainly by inducing podocyte injury. Convincing evidence indicates that the mTOR inhibitor rapamycin could play a fundamental role in protection against podocyte injury. Nestin, a major cytoskeletal protein, is stably expressed in podocytes and correlates with podocyte damage. The purpose of this study was to investigate the effect of rapamycin on podocyte injury induced by Ang II and to clarify the role and mechanism of nestin in the protective effect of rapamycin of podocyte injury.

Methods and results: We established an Ang II perfusion animal model, and the effects of rapamycin treatment on podocytes were investigated in vivo. In vitro, podocytes were stimulated with Ang II and rapamycin to observe podocyte injury, and nestin-siRNA was transfected to investigate the underlying mechanisms. We observed that Ang II induced podocyte injury both in vivo and in vitro, whereas rapamycin treatment relieved Ang II-induced podocyte injury. We further found that nestin co-localized with p-mTOR in glomeruli, and the protective effect of rapamycin was reduced by nestin-siRNA in podocytes. Moreover, co-IP indicated the interaction between nestin and p-mTOR, and nestin could affect podocyte injury via the mTOR/P70S6K signaling pathway.

Conclusion: We demonstrated that rapamycin attenuated podocyte apoptosis via upregulation of nestin expression through the mTOR/P70S6K signaling pathway in an Ang II-induced podocyte injury.

Keywords: Ang II; Apoptosis; Nestin; Podocyte injury; Rapamycin.

MeSH terms

  • Angiotensin II / metabolism
  • Angiotensin II / pharmacology
  • Animals
  • Apoptosis
  • Nestin / genetics
  • Nestin / metabolism
  • Podocytes* / metabolism
  • Sirolimus / pharmacology
  • Up-Regulation

Substances

  • Nestin
  • Angiotensin II
  • Sirolimus